— Why it moved
Why LABT Stock More Than Doubled Today — November 5, 2026
Lakewood-Amedex Biotherapeutics cleaned up its Series C preferred shares, triggering a high-volume momentum spike on a micro-float.
What moved LABT stock
Lakewood-Amedex Biotherapeutics is a micro-cap biotech developer. The company announced it paid $1.27 million to redeem all remaining Series C preferred shares. Removing the preferred stock wiped out potential conversion dilution and existing debt, which brought in a wave of momentum traders.
The mechanics
A micro-float of 847,661 shares trading against 754 million shares in volume creates extreme volatility. The stock gapped up 72.68% before the session started, letting retail volume easily overwhelm the thin order book.
LABT by the numbers
The alert window
The alert dropped at 8:46 AM at $0.426. Anyone following the signal had to stomach a brutal 31.7% drawdown down to $0.2909 before the real push started. It took 99 minutes to top out at $0.96 at 10:25 AM, delivering a 125.4% sellable move for anyone who held through the initial drop.
How LABT's move ended
Shares pulled back off the peak as the afternoon wore on, closing at $0.541. That was still up 27.0% from the alert price. Balance sheet housecleaning is good news, but it doesn't solve underlying revenue concerns for a micro-cap biotech.
The tell: Sub-million floats trading hundreds of millions of shares will inflict heavy drawdowns before hitting their intraday peaks.